Low-Dose Amoxicillin Dual-Therapy Combined with Licorice and Lotus Root Powder Helicobacter Pylori Treatment
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Mar 12, 2025
Trial Information
Current as of April 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for Helicobacter pylori (H. pylori) infections, which are caused by a type of bacteria that can lead to stomach problems. The researchers want to see if a combination of low-dose amoxicillin, a common antibiotic, along with licorice and lotus root powder, can effectively treat these infections. This approach is important because some H. pylori strains have become resistant to standard treatments, making it harder to eliminate the bacteria from the stomach.
To participate in this study, you need to be between 18 and 70 years old and have a positive test for H. pylori. You also should not have taken certain medications, like proton pump inhibitors or antibiotics, in the past four weeks. Participants will receive either the new treatment or standard therapy and will be monitored for their health and any side effects. This trial is not yet recruiting, so interested individuals will need to wait for further details on how to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-70 years, regardless of sex; Positive for Helicobacter pylori (Hp); No use of proton pump inhibitors (PPIs), H2-receptor antagonists, antibiotics, or bismuth compounds within the past 4 weeks;
- Exclusion Criteria:
- • A history of gastric or duodenal surgery; Presence of other severe comorbidities, including significant cardiac, hepatic, or renal dysfunction, malignancies, or other serious medical conditions; Allergy to any component of the investigational drug; Pregnant or breastfeeding women; Participation in another drug study within 3 months prior to enrollment in this study; Inability of the patient to accurately describe their symptoms or to comply with the requirements of this study.
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported